TY - JOUR
T1 - Long-Term Cognitive Decline in Dementia with Lewy Bodies in a Large Multicenter, International Cohort
AU - Kramberger, Milica G.
AU - Auestad, Bjørn
AU - Garcia-Ptacek, Sara
AU - Abdelnour, Carla
AU - Olmo, Josep Garre
AU - Walker, Zuzana
AU - Lemstra, Afina W.
AU - Londos, Elisabet
AU - Blanc, Frederic
AU - Bonanni, Laura
AU - McKeith, Ian
AU - Winblad, Bengt
AU - De Jong, Frank Jan
AU - Nobili, Flavio
AU - Stefanova, Elka
AU - Petrova, Maria
AU - Falup-Pecurariu, Cristian
AU - Rektorova, Irena
AU - Bostantjopoulou, Sevasti
AU - Biundo, Roberta
AU - Weintraub, Daniel
AU - Aarsland, Dag
PY - 2017
Y1 - 2017
N2 - Background/Objective: The aim of this study was to describe the rate and clinical predictors of cognitive decline in dementia with Lewy bodies (DLB), and compare the findings with Alzheimer's disease (AD) and Parkinson's disease dementia (PDD) patients. Methods: Longitudinal scores for the Mini-Mental State Examination (MMSE) in 1,290 patients (835 DLB, 198 PDD, and 257 AD) were available from 18 centers with up to three years longitudinal data. Linear mixed effects analyses with appropriate covariates were used to model MMSE decline over time. Several subgroup analyses were performed, defined by anti-dementia medication use, baseline MMSE score, and DLB core features. Results: The mean annual decline in MMSE score was 2.1 points in DLB, compared to 1.6 in AD (p=0.07 compared to DLB) and 1.8 in PDD (p=0.19). Rates of decline were significantly higher in DLB compared to AD and PDD when baseline MMSE score was included as a covariate, and when only those DLB patients with an abnormal dopamine transporter SPECT scan were included. Decline was not predicted by sex, baseline MMSE score, or presence of specific DLB core features. Conclusions: The average annual decline in MMSE score in DLB is approximately two points. Although in the overall analyses there were no differences in the rate of decline between the three neurodegenerative disorders, there were indications of a more rapid decline in DLB than in AD and PDD. Further studies are needed to understand the predictors and mechanisms of cognitive decline in DLB.
AB - Background/Objective: The aim of this study was to describe the rate and clinical predictors of cognitive decline in dementia with Lewy bodies (DLB), and compare the findings with Alzheimer's disease (AD) and Parkinson's disease dementia (PDD) patients. Methods: Longitudinal scores for the Mini-Mental State Examination (MMSE) in 1,290 patients (835 DLB, 198 PDD, and 257 AD) were available from 18 centers with up to three years longitudinal data. Linear mixed effects analyses with appropriate covariates were used to model MMSE decline over time. Several subgroup analyses were performed, defined by anti-dementia medication use, baseline MMSE score, and DLB core features. Results: The mean annual decline in MMSE score was 2.1 points in DLB, compared to 1.6 in AD (p=0.07 compared to DLB) and 1.8 in PDD (p=0.19). Rates of decline were significantly higher in DLB compared to AD and PDD when baseline MMSE score was included as a covariate, and when only those DLB patients with an abnormal dopamine transporter SPECT scan were included. Decline was not predicted by sex, baseline MMSE score, or presence of specific DLB core features. Conclusions: The average annual decline in MMSE score in DLB is approximately two points. Although in the overall analyses there were no differences in the rate of decline between the three neurodegenerative disorders, there were indications of a more rapid decline in DLB than in AD and PDD. Further studies are needed to understand the predictors and mechanisms of cognitive decline in DLB.
KW - Dementia with Lewy bodies
KW - international cohort
KW - long-term cognitive decline
KW - multicenter study
UR - http://www.scopus.com/inward/record.url?scp=85017347050&partnerID=8YFLogxK
U2 - 10.3233/JAD-161109
DO - 10.3233/JAD-161109
M3 - Article
C2 - 28304294
AN - SCOPUS:85017347050
SN - 1387-2877
VL - 57
SP - 787
EP - 795
JO - Journal of Alzheimer's Disease
JF - Journal of Alzheimer's Disease
IS - 3
ER -